Doug Treco Treco
Chief Executive Officer chez INOZYME PHARMA, INC.
Fortune : 294 614 $ au 31/03/2024
Profil
Douglas A.
Treco is the founder of Transkaryotic Therapies, Inc., which was founded in 1988.
He held the title of Senior Vice President-Research & Development from 1988 to 2005.
He is also the founder of Ra Pharmaceuticals, Inc., which was founded in 2008.
He served as the President & Chief Executive Officer in 2020.
Currently, Dr. Treco is the Chairman & Chief Executive Officer at Inozyme Pharma, Inc. since 2023.
He is also the Lead Independent Director at CRISPR Therapeutics AG since 2021.
Additionally, he holds positions as a Scientific Advisor at LSV Capital Management LLC and as a Special Advisor at 3CC Management LLC.
In the past, Dr. Treco served as the Chief Executive Officer & Director at Alchemab Therapeutics Ltd.
from 2021 to 2022.
He was also a Director at Xcellerex, Inc. Furthermore, he worked as an Entrepreneur-in-Residence at Morgenthaler Management Corp.
from 2008 to 2014.
Dr. Treco obtained a doctorate degree from Stony Brook University in 1984.
He also holds an undergraduate degree from the University of Delaware, which he received in 1979.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
INOZYME PHARMA, INC.
0,03% | 02/04/2024 | 20 665 ( 0,03% ) | 158 294 $ | 31/03/2024 |
CRISPR THERAPEUTICS AG
0,00% | 15/03/2024 | 2 000 ( 0,00% ) | 136 320 $ | 31/03/2024 |
Postes actifs de Doug Treco Treco
| Sociétés | Poste | Début |
|---|---|---|
| CRISPR THERAPEUTICS AG | Director/Board Member | 11/06/2020 |
| INOZYME PHARMA, INC. | Chief Executive Officer | 01/04/2023 |
LSV CAPITAL MANAGEMENT LLC
 LSV CAPITAL MANAGEMENT LLC Investment ManagersFinance LSV Capital Management LLC (Lightstone Ventures) is a venture capital firm founded in 2012. The firm is headquartered in Menlo Park, California. | Consultant / Advisor | - |
3CC Management LLC
 3CC Management LLC Investment ManagersFinance 3CC Management LLC (Third Culture Capital) is a venture capital firm founded in 2020 by Julien L. Pham. The firm is headquartered in Boston, Massachusetts. | Consultant / Advisor | - |
Anciens postes connus de Doug Treco Treco
| Sociétés | Poste | Fin |
|---|---|---|
Alchemab Therapeutics Ltd.
 Alchemab Therapeutics Ltd. BiotechnologyHealth Technology Alchemab Therapeutics Ltd. engages in developing of antibodies. It focuses on discovering and developing novel therapeutics for patients. The company was founded in 2019 and is headquartered in Kings Cross, the Unite Kingdom. | Chief Executive Officer | 26/05/2022 |
| RA PHARMACEUTICALS, INC. | Founder | 01/07/2020 |
Morgenthaler Management Corp.
 Morgenthaler Management Corp. Investment ManagersFinance Morgenthaler Management Corp (Morgenthaler Management) is a venture capital and private equity firm founded in 1968 by David Morgenthaler. The firm is headquartered in Portola Valley, California. | Private Equity Investor | 31/01/2014 |
Transkaryotic Therapies, Inc.
 Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | Founder | 01/01/2005 |
Xcellerex, Inc.
 Xcellerex, Inc. Pharmaceuticals: MajorHealth Technology Xcellerex, Inc. manufactures and provides equipment to produce bio-molecules. Its products and services include FlexFactory, a bioprocess manufacturing platform that handles the production of bio-products, such as vaccines, yeast and insulins. The company was founded by Parrish M. Galliher in 2002 and was headquartered in Marlborough, MA. | Director/Board Member | - |
Formation de Doug Treco Treco
| Stony Brook University | Doctorate Degree |
| University of Delaware | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| CRISPR THERAPEUTICS AG | Health Technology |
| INOZYME PHARMA, INC. | Health Technology |
| Entreprise privées | 7 |
|---|---|
Transkaryotic Therapies, Inc.
Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | Commercial Services |
Xcellerex, Inc.
Xcellerex, Inc. Pharmaceuticals: MajorHealth Technology Xcellerex, Inc. manufactures and provides equipment to produce bio-molecules. Its products and services include FlexFactory, a bioprocess manufacturing platform that handles the production of bio-products, such as vaccines, yeast and insulins. The company was founded by Parrish M. Galliher in 2002 and was headquartered in Marlborough, MA. | Health Technology |
Ra Pharmaceuticals, Inc.
 Ra Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ra Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of peptide-based drugs. It uses Extreme Diversity platform that allows to produce synthetic macrocyclic peptides. The company was founded by James W. Broderick and Douglas A. Treco on June 27, 2008 and is headquartered in Cambridge, MA. | Health Technology |
Morgenthaler Management Corp.
Morgenthaler Management Corp. Investment ManagersFinance Morgenthaler Management Corp (Morgenthaler Management) is a venture capital and private equity firm founded in 1968 by David Morgenthaler. The firm is headquartered in Portola Valley, California. | Finance |
Alchemab Therapeutics Ltd.
Alchemab Therapeutics Ltd. BiotechnologyHealth Technology Alchemab Therapeutics Ltd. engages in developing of antibodies. It focuses on discovering and developing novel therapeutics for patients. The company was founded in 2019 and is headquartered in Kings Cross, the Unite Kingdom. | Health Technology |
3CC Management LLC
3CC Management LLC Investment ManagersFinance 3CC Management LLC (Third Culture Capital) is a venture capital firm founded in 2020 by Julien L. Pham. The firm is headquartered in Boston, Massachusetts. | Finance |
LSV CAPITAL MANAGEMENT LLC
LSV CAPITAL MANAGEMENT LLC Investment ManagersFinance LSV Capital Management LLC (Lightstone Ventures) is a venture capital firm founded in 2012. The firm is headquartered in Menlo Park, California. | Finance |
